Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:CDT NASDAQ:GRTX NASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40+6.6%$0.55$0.30▼$3.42$16.31M-1.8846,973 shs422 shsCDTCDT Equity$0.85+5.6%$3.16$0.74▼$610.00$3.91M1.442.66 million shs384,294 shsGRTXGalera Therapeutics$0.10-1.0%$0.08$0.02▼$0.15$16.04M2.64206,149 shs2,590 shsKTTAPasithea Therapeutics$0.62-2.9%$0.74$0.28▼$2.06$15.92M0.25410,935 shs450,665 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-6.39%-18.46%-18.46%-14.75%-65.27%CDTCDT Equity-5.01%-26.82%-64.38%-95.17%-99.88%GRTXGalera Therapeutics-0.99%-4.58%+11.23%+132.56%+286.10%KTTAPasithea Therapeutics-1.05%-7.89%-24.11%-19.22%-30.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40+6.6%$0.55$0.30▼$3.42$16.31M-1.8846,973 shs422 shsCDTCDT Equity$0.85+5.6%$3.16$0.74▼$610.00$3.91M1.442.66 million shs384,294 shsGRTXGalera Therapeutics$0.10-1.0%$0.08$0.02▼$0.15$16.04M2.64206,149 shs2,590 shsKTTAPasithea Therapeutics$0.62-2.9%$0.74$0.28▼$2.06$15.92M0.25410,935 shs450,665 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-6.39%-18.46%-18.46%-14.75%-65.27%CDTCDT Equity-5.01%-26.82%-64.38%-95.17%-99.88%GRTXGalera Therapeutics-0.99%-4.58%+11.23%+132.56%+286.10%KTTAPasithea Therapeutics-1.05%-7.89%-24.11%-19.22%-30.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/ACDTCDT Equity 1.00SellN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/AKTTAPasithea Therapeutics 2.00Hold$3.00383.87% UpsideCurrent Analyst Ratings BreakdownLatest CDT, ANEB, GRTX, and KTTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/ACDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/ACDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/AGRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%8/12/2026 (Estimated)KTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)Latest CDT, ANEB, GRTX, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24CDTCDT EquityN/A0.340.34GRTXGalera TherapeuticsN/A9.749.74KTTAPasithea TherapeuticsN/A35.4135.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%CDTCDT Equity3.29%GRTXGalera Therapeutics50.77%KTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%CDTCDT Equity10.78%GRTXGalera Therapeutics12.90%KTTAPasithea Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableCDTCDT Equity34.86 million4.33 millionNot OptionableGRTXGalera Therapeutics30160.43 million47.38 millionOptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableCDT, ANEB, GRTX, and KTTA HeadlinesRecent News About These CompaniesPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)June 2 at 7:02 AM | globenewswire.comPasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on WednesdayMay 27, 2026 | americanbankingnews.comQ2 EPS Estimate for Pasithea Therapeutics Lifted by AnalystMay 25, 2026 | americanbankingnews.comPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN ...April 1, 2026 | markets.businessinsider.comPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityApril 1, 2026 | globenewswire.comPasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptFebruary 27, 2026 | seekingalpha.comPasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026February 17, 2026 | quiverquant.comQPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | globenewswire.comPasithea Therapeutics Shareholders Approve Expanded Equity AuthorizationJanuary 28, 2026 | tipranks.comPasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced CancerJanuary 13, 2026 | quiverquant.comQPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesJanuary 13, 2026 | globenewswire.comPasithea Therapeutics (KTTA) price target increased by 50.00% to 3.06December 21, 2025 | msn.comPasithea Therapeutics Regains Nasdaq ComplianceDecember 15, 2025 | tipranks.comHC Wainwright & Co. initiates coverage of Pasithea Therapeutics (KTTA) with buy recommendationDecember 8, 2025 | msn.comLawrence Steinman Bought 201% More Shares In Pasithea TherapeuticsDecember 4, 2025 | finance.yahoo.comInsiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10%December 4, 2025 | finance.yahoo.comPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockDecember 2, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDT, ANEB, GRTX, and KTTA Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.40 +0.02 (+6.64%) As of 01:26 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.CDT Equity NASDAQ:CDT$0.85 +0.05 (+5.59%) Closing price 04:00 PM EasternExtended Trading$0.82 -0.03 (-3.18%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Galera Therapeutics NASDAQ:GRTX$0.10 0.00 (-0.99%) As of 03:22 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Pasithea Therapeutics NASDAQ:KTTA$0.62 -0.02 (-2.85%) Closing price 03:59 PM EasternExtended Trading$0.62 -0.01 (-0.81%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
